Compare Pfizer Inc (PFE) vs Ulta Beauty Inc (ULTA) Price & Performance

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

ULTA Beauty trades at $549.23, down 2.64% today, but maintains strong technical support near $539-$530. The company reported solid Q2 2026 earnings with EPS of $6.55 beating expectations of $6.22, while raising full-year guidance. Revenue growth continues at 8.9% year-over-year, though profit margins show slight compression from 12.17% in 2023 to 10.63% in 2025. Analyst consensus remains bullish with a $644 price target representing 17% upside potential.

ULTA presents a compelling growth story with consistent earnings beats and strong institutional support, but faces margin pressure and competitive retail headwinds. The stock's current valuation at 20.54 P/E appears reasonable given its 46.12% ROE and market leadership position. Key risks include consumer spending sensitivity and execution challenges in maintaining growth momentum.